Cargando…

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

PURPOSE: In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with leptomeningeal metastases (LMs) from EGFR-mutated (EGFRm) advanced non–small-cell lung cancer (NSCLC) whose disease had prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, James C.H., Kim, Sang-We, Kim, Dong-Wan, Lee, Jong-Seok, Cho, Byoung Chul, Ahn, Jin-Seok, Lee, Dae H., Kim, Tae Min, Goldman, Jonathan W., Natale, Ronald B., Brown, Andrew P., Collins, Barbara, Chmielecki, Juliann, Vishwanathan, Karthick, Mendoza-Naranjo, Ariadna, Ahn, Myung-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	RAPID COMMUNICATIONS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030895/ https://www.ncbi.nlm.nih.gov/pubmed/31809241 http://dx.doi.org/10.1200/JCO.19.00457

Ejemplares similares

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
por: Kim, Hye Ryeon, et al.
Publicado: (2023)

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
por: Ahn, Myung-Ju, et al.
Publicado: (2020)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

Autoimmune limbic encephalitis combined with leptomeningeal metastases of non-small cell lung cancer: treatment response to osimertinib, immunoglobulin, rituximab, and tocilizumab
por: Lee, Seolah, et al.
Publicado: (2023)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for leptomeningeal metastasis and successful treatment with osimertinib: A case report and literature review
por: Sakurai, Takeo, et al.
Publicado: (2020)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer
por: Vishwanathan, Karthick, et al.
Publicado: (2019)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
por: Xu, Haiyan, et al.
Publicado: (2021)

Primary Diffuse Leptomeningeal Gliosarcomatosis
por: Moon, Ju Hyung, et al.
Publicado: (2015)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
por: Ekman, Simon, et al.
Publicado: (2023)

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

A pipeline to characterize p53 effectors by integrative cistrome and transcriptome analysis in a genetically-defined organoid model
por: Shin, June-Ha, et al.
Publicado: (2023)

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
por: Takeda, Takayuki, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor (EGFR) Expression in Operable Non-small Cell Lung Carcinoma
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
por: Lim, Sun Min, et al.
Publicado: (2023)

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Acute liver injury induces expression of FGF23 in hepatocytes via orphan nuclear receptor ERRγ signaling
por: Jung, Yoon Seok, et al.
Publicado: (2022)

Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities
por: Park, Yae Won, et al.
Publicado: (2023)

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment
por: Vishwanathan, Karthick, et al.
Publicado: (2020)

METHYLATION STATUS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE IN LUNG CARCINOMA CELLS
por: Gamou, Shinobu, et al.
Publicado: (1988)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
por: Merkhofer, Cristina M., et al.
Publicado: (2021)

Salvage therapy of osimertinib plus anlotinib in advanced lung adenocarcinoma with leptomeningeal metastasis: A case report
por: Wu, Kai, et al.
Publicado: (2022)

Targeted Base Editing via RNA-Guided Cytidine Deaminases in Xenopus laevis Embryos
por: Park, Dong-Seok, et al.
Publicado: (2017)

Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma
por: Shin, Sang-Yong, et al.
Publicado: (2016)

Specific Expression of Aplysia Phosphodiesterase 4 in Bag Cells Revealed by in situ Hybridization Analysis
por: Jang, Deok-Jin, et al.
Publicado: (2015)

Expression of cripto, a Novel Gene of the Epidermal Growth Factor Family, in Human Gastrointestinal Carcinomas
por: Kuniyasu, Hiroki, et al.
Publicado: (1991)

Ongoing rabies outbreak in dogs of unprecedented scale and human cases in Nelson Mandela Bay Municipality, South Africa, up to 13 February 2022
por: Ravensberg, Matthijs F, et al.
Publicado: (2022)

Predicting Cyanobacterial Blooms Using Hyperspectral Images in a Regulated River
por: Ahn, Jung Min, et al.
Publicado: (2021)

Can Complex Visual Discrimination Deficits in Amnesia Be Attributed to the Medial Temporal Lobe? An Investigation Into the Effects of Medial Temporal Lobe Damage on Brain Connectivity
por: Rudebeck, Sarah R, et al.
Publicado: (2013)

Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor
por: Nakayashiki, Norihisa, et al.
Publicado: (2000)

Detection of Epidermal Growth Factor Receptor Gene Amplification in Human Squamous Cell Carcinomas Using Fluorescence in situ Hybridization
por: Shimizu, Nobuyoshi, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_2v6dv2o4p170q30vj4gdoodklf